Omesdafexor

Omesdafexor
Clinical data
Other names	MET409
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[3-(1-cyclopropylpyrazol-4-yl)phenyl]-4-hydroxy-N-[[4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]cyclohexane-1-carboxamide;
CAS Number	2244440-85-3;
PubChem CID	135329968;
ChemSpider	128921646;
UNII	E05WEZ4XLE;
Chemical and physical data
Formula	C34H43N3O3
Molar mass	541.736 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N(C[C@@H]1CC[C@H](CC1)C2=CC(C)=C(OC)C=C2)(C(=O)[C@@H]3CC[C@@H](O)CC3)C4=CC(=CC=C4)C5=CN(N=C5)C6CC6;
	InChI InChI=1/C34H43N3O3/c1-23-18-28(12-17-33(23)40-2)25-8-6-24(7-9-25)21-36(34(39)26-10-15-32(38)16-11-26)31-5-3-4-27(19-31)29-20-35-37(22-29)30-13-14-30/h3-5,12,17-20,22,24-26,30,32,38H,6-11,13-16,21H2,1-2H3/t24-,25-,26-,32-; Key:RPBNLMPTFCTXRQ-RYYHSFPWNA-N;

Omesdafexor (MET409) is a small-molecule farnesoid X receptor (FXR) agonist developed for nonalcoholic steatohepatitis and colitis.^[2]^[3]

References

↑ Harrison, S. A.; Bashir, M. R.; Lee, K. J.; Shim-Lopez, J.; Lee, J.; Wagner, B.; Smith, N. D.; Chen, H. C.; Lawitz, E. J. (2021). "A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis". Journal of Hepatology. 75 (1): 25–33. doi:10.1016/j.jhep.2021.01.047. PMID 33581174.
↑ Liu, Xueqing; O'Connell, Robert; Bendele, Alison; Walker, Melissa; Ohlsen, Connor; Govek, Steve; Nagasawa, Johnny; Douglas, Karensa; Milik, Angelica; Lu, Nhin; Qian, Jing; Ortiz, Alvaro; Chai, Pauline; Zook, Douglas; Lee, Kyoung-Jin; Smith, Nicholas; Wagner, Brandee; Song, Ken (February 2020). "P153 Met642, an Oral FXR Agonist, Improves Colitis Induced by Adoptive T-Cell Transfer". Gastroenterology. 158 (3): S11. doi:10.1053/j.gastro.2019.11.062.
↑ "Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients". Retrieved 2 December 2023.